Expression of osteopontin messenger RNA by macrophages in ovarian serous papillary cystadenocarcinoma: A possible association with calcification of psammoma bodies

Maki, Masahiko; Hirota, Seiichi; Kaneko, Yoshiyasu; Morohoshi, Toshio

doi:10.1046/j.1440-1827.2000.01075.x

Cited by 42 publications

(39 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Elevated OPN concentrations are also associated with increased tumor burden and decreased survival in breast and prostate cancer (13,28). Different histological subtypes of ovarian carcinoma exhibit different patterns, as follows: serous tumors appear to actively secrete OPN to psammoma bodies whereas mucinous variants exhibit high levels of OPN in the cytoplasm (15,29). The apparent clinical utility of OPN in several human cancers supports our observation that this marker has potential applications during the treatment and follow-up of patients with ovarian cancer.…”

Section: Discussionsupporting

confidence: 72%

Osteopontin as an Adjunct to CA125 in Detecting Recurrent Ovarian Cancer

Schorge

Drake

Lee

et al. 2004

Clinical Cancer Research

View full text Add to dashboard Cite

Purpose: CA125 is currently the only tumor marker to have a validated role in the postoperative monitoring of ovarian cancer. Osteopontin (OPN) is a putative plasma biomarker that was recently identified using high-throughput cDNA microarray technology. The purpose of this study was to test the hypothesis that OPN is a clinically useful adjunct to CA125 in detecting recurrent ovarian cancer.Experimental Design: Thirty-eight ovarian cancer patients had a single pretreatment blood sample and 200 postoperative specimens were prospectively collected during chemotherapy and follow-up. OPN measurements were performed using an enzyme-linked immunoassay, and CA125 levels were concurrently obtained. Wilcoxon's signed ranksum test was used to perform paired comparisons between pretreatment and postoperative OPN and CA125 measurements. Longitudinal mixed effects polynomial models were used to determine whether OPN and CA125 levels correlated with the development of recurrent ovarian cancer. Results:The median pretreatment OPN level was 178 ng/ml (range, 12-3468) and the median CA125 measurement was 812 units/ml (range, 12-81,500). There was a trend for OPN levels to decline after treatment was initiated (P ‫؍‬ 0.07), but decreasing CA125 measurements were more consistently observed (P ‫؍‬ 0.0009). The quadratic functional trends of OPN and CA125 were each highly significant (P < 0.0001). Although inferior to CA125 in predicting clinical response to therapy, OPN rose earlier in 90% (95% confidence interval, 56 -100%) of the patients developing recurrent disease (median lead time, 3 months).Conclusions: OPN may be a clinically useful adjunct to CA125 in detecting recurrent ovarian cancer.

show abstract

Section: Discussionsupporting

confidence: 72%

Osteopontin as an Adjunct to CA125 in Detecting Recurrent Ovarian Cancer

Schorge

Drake

Lee

et al. 2004

Clinical Cancer Research

View full text Add to dashboard Cite

show abstract

“…These genes play a prominent role in bone and calcium metabolism and the formation of psammoma bodies in meningiomas (45) and ovarian serous papillary (46) and thyroid carcinomas (47). In addition, SPARC and MSN are also associated with tumor invasiveness and metastasis (48,49).…”

Section: Discussionmentioning

confidence: 99%

Gene Expression Profiling of Differentiated Thyroid Neoplasms

Chevillard¹,

Ugolin²,

Vielh

et al. 2004

Clinical Cancer Research

120

View full text Add to dashboard Cite

Purpose: The purpose of this research was to identify novel genes that can be targeted as diagnostic and clinical markers of differentiated thyroid tumors.Experimental Design: Gene expression analysis using microarray platform was performed on 6 pathologically normal thyroid samples and 12 primary follicular and papillary thyroid neoplasms. Microarrays containing probes for 5,760 human full-length cDNAs were used for hybridization with total RNA from normal and tumor thyroid samples labeled with Cy3-dUTP and Cy5-dUTP, respectively. Scanned array images were recorded, and data analysis was performed. Selected sets of differentially expressed genes were analyzed using quantitative real-time reverse transcription-PCR for verification.Results: We identified 155 genes that differentiate histologically normal thyroid tissues from benign and malignant thyroid neoplasms. Of these 75 genes were differentiated between follicular neoplasms (adenoma and carcinoma) and the follicular variant of papillary carcinoma. Purely follicular neoplasms (adenomas and carcinomas) shared many genetic profiles, and only 43 genes were distinctly different between these tumors. Hierarchical cluster analysis also differentiated conventional papillary carcinoma from its follicular variant and follicular tumors. The differentially expressed genes were composed of members of cell differentiation, adhesion, immune response, and proliferation associated pathways. Quantitative real-time reverse transcription-PCR analysis of selected genes corroborated the microarray expression results.Conclusions: Our study show the following: (1) differences in gene expression between tumor and nontumor bearing normal thyroid tissue can be identified, (2) a set of genes differentiate follicular neoplasm from follicular variant of papillary carcinoma, (3) follicular adenoma and carcinoma share many of the differentiated genes, and (4) gene expression differences identify conventional papillary carcinoma from the follicular variant.

show abstract

“…Several researchers have shown the presence of osteopontin in microcalcifications in breast tumor tissues (172,173) and in ectopic calcification in other tumors, such as serous papillary cystadenocarcinoma of the ovary, meningiomas, papillary carcinoma of the thyroid, and pilomatricomas (174)(175)(176).…”

Section: The Significance Of Osteopontin In Human Cancermentioning

confidence: 99%

The Role of Osteopontin in Tumor Progression and Metastasis in Breast Cancer

Rodrigues

Teixeira

Schmitt

et al. 2007

Cancer Epidemiology, Biomarkers &Amp; Prevention

206

144

View full text Add to dashboard Cite

The use of cancer biomarkers to anticipate the outlines of disease has been an emerging issue, especially as cancer treatment has made such positive steps in the last few years. Progress in the development of consistent malignancy markers is imminent because advances in genomics and bioinformatics have allowed the examination of immense amounts of data. Osteopontin is a phosphorylated glycoprotein secreted by activated macrophages, leukocytes, and activated T lymphocytes, and is present in extracellular fluids, at sites of inflammation, and in the extracellular matrix of mineralized tissues. Several physiologic roles have been attributed to osteopontin, i.e., in inflammation and immune function, in mineralized tissues, in vascular tissue, and in kidney. Osteopontin interacts with a variety of cell surface receptors, including several integrins and CD44. Binding of osteopontin to these cell surface receptors stimulates cell adhesion, migration, and specific signaling functions. Overexpression of osteopontin has been found in a variety of cancers, including breast cancer, lung cancer, colorectal cancer, stomach cancer, ovarian cancer, and melanoma. Moreover, osteopontin is present in elevated levels in the blood and plasma of some patients with metastatic cancers. Therefore, suppression of the action of osteopontin may confer significant therapeutic activity, and several strategies for bringing about this suppression have been identified. This review looks at the recent advances in understanding the possible mechanisms by which osteopontin may contribute functionally to malignancy, particularly in breast cancer. Furthermore, the measurement of osteopontin in the blood or tumors of patients with cancer, as a way of providing valuable prognostic information, will be discussed based on emerging clinical data. (Cancer Epidemiol Biomarkers Prev 2007;16(6):1087 -97)

show abstract

Expression of osteopontin messenger RNA by macrophages in ovarian serous papillary cystadenocarcinoma: A possible association with calcification of psammoma bodies

Cited by 42 publications

References 14 publications

Osteopontin as an Adjunct to CA125 in Detecting Recurrent Ovarian Cancer

Osteopontin as an Adjunct to CA125 in Detecting Recurrent Ovarian Cancer

Gene Expression Profiling of Differentiated Thyroid Neoplasms

The Role of Osteopontin in Tumor Progression and Metastasis in Breast Cancer

Contact Info

Product

Resources

About